[Emerging and pandemic of influenza A[H1N1]]

Influenza is one of the known viral infectious diseases, which has killed millions of peoples during pandemics, epidemics and sporadic forms. One of the most remarkable features of influenza virus is the frequency of changes in antigenicity. Alteration of the antigen structure of the virus leads to infection with variants to which little or no resistance is present in the population at risk. Pandemics of influenza type A, result from the emergence of a new virus which the population contains no or limited immunity to it. The interval between pandemics is 10-30 years. But Influenza virus has been causing epidemics of febrile respiratory disease every 1 to 3 years. Pandemic [H1N1] 2009 is a new virus that has not circulated among human population before. This virus is different from previous or current human seasonal influenza viruses. Influenza type A[H1N1] virus is transmitted by inhaling infected droplets expelled by coughing or sneezing or by touching contaminated hands or surfaces as the same as the normal seasonal flu. The symptoms and signs of A[H1N1] influenza are as similar as seasonal influenza and include fever, coughing, runny nose and sore throat. Some people have also reported, nausea, vomiting and diarrhea. People with existing cardiovascular disease, respiratory disease, diabetes and cancer are at higher risk of serious complications. Asthma and other respiratory disease are other underlying conditions associated with severe disease. Pregnant women are at higher risk for more severe disease and obesity may be another risk factor for severe disease. To prevent spread, people should cover their mouth and nose when coughing or sneezing, stay at home when they are unwell, clean their hands regularly, and avoid crowded areas if possible. The pandemic virus is currently susceptible to neuraminidase inhibitors; Oseltamivir and Zanamivir but resistant to Amantadine and Rimantadine. Ministry of health and medical education, Center for Infectious Diseases Management in Islamic Republic of Iran is ready for control and management of novel influenza A[H1N1]

[Prevalence of hepatitis B virus [HBV] infection among Iranian prisoners during 2001-2005]

To determine the prevalence of Hepatitis B Virus [HBV] infection, as a blood borne viral infection, among prisoners and its associated factors in Iran. In this cross sectional study, 5317 inmates, who had stayed in prison for at least 3 months, were tested in 7 provinces from 2001 to 2005. The degree of contamination with HBV and its association with age and drug abuse were evaluated. The frequency of contamination with HBV ranged from 1% to 15% in different prisons. Overall frequency was 6.7% [95% CI: 6.1%-7.4%]. The crude and adjusted association between HBV infection and age was studied. While adjusted for prisons. The result showed no significant association between age and HBV infection [P = 0.88] based on Mantel Heanszel test. However, there was a significant association between HBV infection and drug abuse in two out of seven prisons [where the data was available]. The frequency of contamination with HBV infection is relatively high [more than twice] in prisons comparing to the general population [6.7% VS 2.8%]. Planning regular screening, preventive practices such as vaccination against HBV in prisoners as well as easy access to therapeutic facilities are highly recommended